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Human papillomavirus (HPV) is the cause of a fraction of head and neck squamous cell car-
cinoma. Although this relation is well-known, it is still not clear the role of HPV in premalig-
nant oral lesions such as oral lichen planus (OLP) and dysplasia. We aimed to evaluate the
HPV-DNA prevalence and type distribution in a set of oral biopsies obtained from patients
diagnosed with OLP and dysplasia, as well as the role of HPV in these lesions.
Methods
A retrospective cohort of all premalignant oral lesions consecutively diagnosed from March
30th 1995 to May 21st 2014 at Hospital of Bellvitge and Odontological University Hospital of
Bellvitge was identified and classified in four groups: OLP (groups 1 and 2) and dysplasias
(groups 3 and 4) that progressed or not to invasive cancer during follow-up. A random selec-
tion targeting 25 cases was aimed to be performed for each group. All selected cases were
subjected to pathological evaluation, DNA quality control and HPV-DNA detection. HPV-
DNA positive samples were further subject to p16INK4a analysis.
Results
A total of 83 cases yielded a valid HPV-DNA result. From those, 7 and 34 cases were OLP
that progressed or not to invasive cancer during follow-up, whereas 24 and 18 cases were
displasias that progressed or not to invasive cancer during follow-up, respectively. HPV-
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DNA was detected in 4 samples (3 dysplastic lesions and 1 OLP). Two samples were
HPV16 positive (2%), 1 sample HPV18 positive (1%) and 1 sample (1%) was HPV indeter-
minate. Two out of four HPV-DNA positive cases had high p16INK4a expression and none of
the HPV positive cases progressed to invasive cancer during long-term follow-up.
Conclusions
We found a low HPV-DNA attributable fraction in premalignant lesions of the oral cavity,
suggesting that HPV is unlikely to play a significant role in oral carcinogenesis in our setting.
Introduction
Oral squamous cell carcinoma (OSCC) is the most common type of head and neck squamous
cell carcinoma (HNSCC), with an estimated 200,000 new cases every year [1]. OSCC may be
preceded by premalignant oral lesions, including mucosal lesions such as oral lichen planus
(OLP), leukoplakia, erythroplakia or more widespread conditions, some of them showing dif-
ferent grades of dysplasia at histopathological analysis [2].
HPV attributable fractions in OSCC are estimated at 2.2%, substantially lower than those
for oropharyngeal squamous cell carcinoma, estimated a 30,8% [1]. The relationship between
HPV infection and premalignant oral lesions is still controversial [2,3], as it is the identifica-
tion of HPV-related precursor lesions in the head and neck [4]. Some authors pointed out that
there are huge geographic differences in prevalence of HPV infection in oral mucosal disorders
worldwide [5], which may be partially explained by differences in case selection, risk factors,
ethnicity, sampling or detection tecniques [6,7].
Premalignant oral lesions include oral leucoplakia, oral erythroplakia, oral proliferative ver-
rucous leukoplakia, oral submucous fibrosis, oral lichen planus (OLP) and actinic cheilitis
[8,9]. In our study we evaluated OLP because it is the most common premalignant condition,
as well as dysplasia, because it is considered a previous stage of progression to invasive cancer
[10]. OLP is a T-cell-mediated chronic inflammatory disease [11] that affects around 1% of
population. Its ethiopathogenesis is poorly understood [8]. Histologically, lesions are charac-
terized by hyperkeratosis, basal layer liquefaction of the oral epithelium-connective tissue
interface and a dense infiltration of a band of lymphocytes [12]. Some studies show that HPV
may play a role in OLP genesis [13,14], but others disagree [15,16]. High-risk HPV16 and
HPV18 are the most prevalent types found in OLP [14,15,17] and its eventual malignant trans-
formation [18]. However, contrary to the OLP subtype, as well as other factors as smoking and
buccal hygiene, the role of high-risk HPV in progression to invasive cancer has not been well
established [19,20,21].
Dysplasia is also considered a potentially malignant disorder, as some studies relate oral
dysplasia with HNSCC [22,23]. It is considered a clinical as well as a pathological concept, as
some lesions such as leucoplakia may show dysplasia at the pathological study [24]. The pro-
portion of HPV-DNA positive cases in dysplasia have found to be heterogeneous (between 6%
to 27.1%) [20,25,26]. Again, the role of HPV in the development of oral dysplasia and its subse-
quent malignancy is not still clear as most of the studies and meta-analyses show discrepant
results [21,25].
We aimed to assess the prevalence of HPV infection in a Spanish series of OLP and dyspla-
sia, the type distribution of HPV-DNA positive cases and the role of the virus in these lesions,
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evaluating if they expressed p16INK4a and progressed to invasive cancer during follow-up or
not.
Materials and methods
Study design and samples
A retrospective cohort study of all patients consecutively diagnosed from March 30th 1995 to
May 21st 2014 with OLP and oral dysplasia at Bellvitge University Hospital and Odontological
University Hospital of Barcelona (Spain) with available clinical data was conducted. All
selected patients had to fulfil pre-established inclusion criteria: to be diagnosed with OLP or
oral dysplasia in the pre-established anatomical locations (base of the tongue, tongue, orophar-
ynx, gingiva, floor of the mouth, palate, cheek mucosa and oral cavity not specified) and not
having had a previous oral cavity cancer or oropharyngeal cancer. Since the causal role of HPV
in HNSCC is only consistently established in oropharyngeal cancer and moreover, the identifi-
cation of HPV-related precursor lesions in the head and neck remains puzzling [4], we consid-
ered pertinent to keep those premalignant lesions in the study. External lip lesions were not
included in the study as they are not considered to be related to HPVs [23]. Data was retrieved
on demographics, smoking and alcohol consumption, clinical and follow-up data. We classi-
fied the whole cohort (n = 421) in four groups: OLP (groups 1 and 2) and dysplasias (groups 3
and 4) that progressed or not to invasive cancer during follow-up, see Table 1. Once the classi-
fication was made, we aimed to test in a first stage a pilot group of 100 cases since we expected
HPV prevalence to be very low. Depending on the observed HPV prevalence, we would decide
to test or not the whole cohort in a second stage. In order to select the pilot group of 100 cases,
we planned to perform a random selection of 25 cases for each group (i.e. groups 1 to 4).
However, there were not 25 but only 7 OLP with available paraffin block that progressed to
invasive cancer during follow up cases in the whole cohort (n = 421). Thus, all those 7 cases
were included. In order to still testing 50 OLP in the pilot, sample was then enriched up to 43
randomly selected OLP that not progressed to invasive cancer during follow up.
It was requested to provide samples using a common protocol from sample selection,
retrieval, processing and shipping to Catalan Institute of Oncology (ICO) [27].
Table 1. Type of lesion and progression to invasive cancer.
Type of lesion Group Total N N pilota
OPL
Did progress to invasive cancer during follow up?
YES 1 25b 7
NO 2 289 34
Dysplasia
Did progress to invasive cancer during follow up?
YES 3 55 24
NO 4 52 18
Total - 421 102c
aIn order to select the pilot cases for each group of lesions to be tested for HPV-DNA, a random selection of 25 cases
was made when possible (i.e. more than 25 cases with available sample in the whole cohort (n = 421) for the specific
group).
bOnly 7 out of 25 with available sample.
cThe selected 102 cases were further evaluated when arrived at ICO as described in the materials and methods section
and finally 83 cases were tested for HPV-DNA (see Fig 1).
OLP: Oral lichen planus
https://doi.org/10.1371/journal.pone.0210070.t001
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Pathology and laboratory procedures
Pathology procedures were performed at Hospital of Bellvitge and ICO and laboratory proce-
dures at the ICO according to a robust and well validated methodology [27–29]. Before being
shipped to ICO, all paraffin embedded samples were revised by the pathologist at origin to
confirm diagnose. Blocks were re-embedded whenever necessary and four paraffin sections
were obtained for each block. In order to assess potential carryover contamination at the local
level, we additionally requested tissue samples of patients with non-HPV related diagnoses
processed in the same laboratory and close to the patients’ diagnosis time. Blocks were pro-
cessed under strict conditions to avoid DNA contamination [27–29]. First and last sections
were stained with haematoxylin and eosin (H&E) for pathological revaluation, which included
confirmation of OLP and dysplasia. A histopathological form was developed for the study by
two pathologists (see S1 Fig).
A sample was determined to be adequate for HPV testing if the lesion of interest was
observed in both H&E-stained sections of the study specimen. Intermediate sections were
used for HPV-DNA detection and genotyping and p16INK4a immunohistochemistry (IHC)
[30]. For HPV-DNA detection and genotyping, samples were first treated with 250 μl of freshly
prepared proteinase K solution to extract DNA. Short polymerase chain reaction (PCR) frag-
ment using biotin labelled SPF10 primers was performed using 10 μl of a 1:10 dilution of the
crude DNA isolate in a final reaction volume of 50 μl. The amplified PCR products were tested
using a probe hybridization step with a cocktail of conservative probes recognizing at least 54
mucosal HPV genotypes for the detection of HPV DNA with a DNA enzyme immunoassay
(DEIA). Optical densities (OD450) were read on a microtitre plate reader and categorized as
HPV-DNA-negative, -positive, or borderline. Borderline samples were run on the DEIA sys-
tem again. The amplimers of the DEIA HPV-DNA-positive samples would have been subse-
quently analysed by reverse hybridization line probe assay (LiPA25) (version 1; Laboratory
Biomedical Products, Rijswijk, the Netherlands). The technique can detect 25 high-risk and
low-risk HPV types (type numbers 6, 11, 16, 18, 31, 33, 34, 35, 39, 40, 42, 43, 44, 45, 51, 52, 53,
54, 56, 58, 59, 66, 68, 70, 74). In order to evaluate DNA quality, the samples were subjected to a
PCR targeting the human tubulin gene, which generated a 65 bp amplicon, the same size as the
SPF10 amplicon used for assessing the presence of HPV-DNA. p16INK4a expression was evalu-
ated on HPV-DNA positive cases using the CINtec histology kit (clone E6H4, Roche mtm lab-
oratories AG, Germany), following the manufacturer’s protocol [27–29]. It is generally
accepted that p16INK4a staining has a high predictive value to identify HPV-related cancers
when the pattern shows a strong and diffuse nuclear and cytoplasmic staining in at least 70%
or more of the tumour [31]. However, for our study in premalignant oral lesions we chosen as
previously [27] the methodology developed by Halec and colleagues [32] where the cut-off for
p16 positivity is a staining greater than 25% in a diffuse or continuous pattern, since we have
observed [27] that using p16INK4a and/or HPV-mRNA in addition to HPV-DNA yielded the
most accurate approximation to judge HPV carcinogenicity in HNSCC also in non-oropha-
ryngeal sites.
Ethics
This study had formal approval by the Ethical Committee for Clinical and Epidemiological
research of our research centre, Hospital of Bellvitge, Catalan Institute of Oncology (ICO),
Odontological University Hospital of Barcelona and Hospital of University of Barcelona
(Comitè Ètic d’Investigació Clínica de l’Hospital Universitari de Bellvitge, L’Hospitalet de Llo-
bregat, Spain). Study implied the use of archival material only, and it did not envisage any con-
tact with the patients. Adequate measures to ensure data protection, confidentiality, patients’
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privacy and anonymization were taken into account. No informed consent was available due
to the retrospective design of the study and the large proportion of deceased and untraceable
patients. However, informed consent was obtained for a single patient diagnosed in 2014
(n = 1).
Results
Fig 1 describes the workflow of the targeted cases, samples collected, processed and finally
tested for HPV-DNA. A total of 464 OPL and dysplasia cases were consecutively diagnosed at
the Pathology Department of Hospital of Bellvitge and Odontological University Hospital of
Barcelona from March 30th 1995 to May 21st 2014. Among these, 43 samples were excluded
because follow-up information was not available. From the resulting 421 cases a total of 102
cases were selected for the pilot study on HPV-DNA assessment as previously described in
material and methods. While a random selection of 25 cases was possible to be performed for
groups 2, 3, 4, only 7 OLP with available paraffin block from the whole cohort progressed to
Fig 1. Algorithm.
https://doi.org/10.1371/journal.pone.0210070.g001
HPV role in premalignant oral lesions in Spain
PLOS ONE | https://doi.org/10.1371/journal.pone.0210070 January 16, 2019 5 / 13
invasive cancer during follow up (see Table 1). Thus, no random selection was possible to be
performed in this case and all 7 cases were included in the pilot study. In order to still testing
50 OLP in the pilot, sample was then enriched up to 43 randomly selected OLP that not pro-
gressed to invasive cancer during follow up.
After pathology evaluation, 19 samples were excluded (3 with no lesion observed, 1 infiltrat-
ing squamous cell carcinoma, 10 hyperkeratosis, 4 ulcerations and 1 hyperplasia). The final
number of cases for each group was: 34 OLP that did not progressed to invasive cancer during
follow up (group 1), 18 dysplasias that did not progressed to invasive cancer during follow up
(group 2), 24 dysplasias that progressed to invasive cancer during follow up (group 3) and 7
OLP that progressed to invasive cancer during follow up (group 4). Two samples from group 2
required a second testing for technique problems and were finally included. All controls were
HPV-negative and all HPV-DNA negative cases were tubulin positive.
Characteristics of the samples are presented in Table 2. Mean age was 60.8 (Standard Devia-
tion SD 11.6) at the moment of diagnosis. Forty-eight (57.8%) cases were male and most of the
patients (36.1%) were diagnosed between 2010 and 2014. More than half of the patients (45,
54.2%) belonged to non-smoker group while 58 (69.9%) belonged to non-drinker group.
Cheek mucosa was the most common anatomical location of the lesions (42.2%). Only 7
patients (8.4%) were diagnosed with a previous neoplasia in other locations than head and
neck area. Regarding to pathology diagnosis, 45 (54.2%) lesions were OLP, whereas 13 (15.7%)
showed low dysplasia, 12 (14.5%) moderate dysplasia and 13 (15.7%) severe dysplasia. Most
cases were treated with surgery (46.8%).
Only four samples were HPV-DNA positive. HPV16 was found in a OLP and in a dysplasia
that did not progressed to invasive cancer during follow up, respectively. HPV18 and undeter-
mined HPV were found in severe and low dysplasia that did not progressed to invasive cancer
during follow up, respectively. Two out of four HPV-DNA positive cases, which were as severe
dysplasia positive for HPV16 and a moderate dysplasia positive for HPV18, showed diffuse
expression of p16INK4a with 25 to 50% of cells stained (Fig 2, patient 1 and 3). Both cases
showed a nuclear basal and ascendant stain.
One HPV16 positive-case was a 33-year-old male (Fig 2, patient 1), smoker and ex-drinker,
HIV-carrier (human immunodeficiency virus) with many comorbidities, who had and unspe-
cific oral lesion at cheek mucosa diagnosed as severe dysplasia with positive p16INK4a stain.
Second HPV16 positive sample (patient 2) was a 60-year-old woman, non-smoker and non-
alcoholic, with no comorbidities, who developed an OLP in the gum that did not degenerate.
The HPV18 positive-case (patient 3) was a 55-year-old smoker and drinker male with many
comorbidities who had a moderate dysplasia in a leucoplakia at floor of the mouth with posi-
tive p16INK4a stain that healed during follow-up. The undetermined HPV case was a 67-year-
old woman, non-smoker and non-alcoholic, with comorbidities presenting a leukoerythropla-
kia lesion in the tongue diagnosed as low-grade dysplasia that resolved within the next 4 years.
Discussion
To our knowledge, this is one of the largest studies about HPV and oral premalignant lesions
tested in a standardized manner with international, robust and well-validated methodology
[27–29]. In Spain, there was only a previous study having tested 35 leukoplakias for HPV-DNA
[33].
Association between HPV and OLP and dysplasia has been suggested but it has not been
well established. In our study, most of the cases were found at oral cavity and the virus was
detected only in 4 cases (4.8%). When examining the positivity by type of lesion, we found one
OPL that did not progressed to invasive cancer during follow up (2.9% of all OLP) and three
HPV role in premalignant oral lesions in Spain
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Table 2. Demographics and clinical characteristics of patients with oral premalignant lesions.
Characteristics OPLa samples (n = 83) No. (%)










Non smoker 45 (54.2)
< 20 cigarettes/day 30 (36.1)
� 20 cigarettes/day 8 (9.6)
Alcohol consumption
Non drinker 58 (69.9)
< 100 grams/day 23 (27.7)
� 100 grams/day 2 (2.4)
Subsite
Gum 10 (12.0)
Cheek mucosa 35 (42.2)
Mobile tongue 22 (26.5)
Floor of the mouth 3 (3.6)






Oral lichen planus 45 (54.2)
Dysplasia low grade 13 (15.7)
Dysplasia moderate grade 12 (14.5)
Dysplasia severe grade 13 (15.7)
Treatment by diagnostic (n = 79)
Oral lichen planus 45 (54.2)






Dysplasia low grade 13 (15.7)
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dysplasias that did not progressed to invasive cancer during follow up (7.1% of all dysplasias).
This low prevalence limited our ability to analyse factors associated with HPV infection. Like-
wise, HPV-DNA has been observed in a small proportion (6.4%) of dysplasias in preliminary
results of a recent Canadian study [20]. Regarding OLP, a low HPV-DNA prevalence was
reported in thirty-seven fresh-frozen tissue biopsy specimens from OLP lesions tested for
HPV-DNA where only one sample was positive [34]. Other studies [35,36] also showed very
low prevalence in OLP and premalignant conditions. On the other hand, a previous systematic
review [25] show a statistically significant twofold difference (23% versus 11%) between HPV
associated with OLP lesions and HPV found in normal tissue. However, there is a high degree
of variation between studies in experimental methods, selection criteria and specimen collec-
tion [37].
Noteworthy, the attributable fraction of HPV in oral cavity cancer has been estimated
between 2.2% [1] and 4.4% [27] and the oral prevalence in healthy population at 4.5% [38].
None of our 4 HPV DNA positive cases progressed to invasive cancer during follow-up. To
date, there is no clear understanding about HPV natural history at premalignant oral lesions
(latency, reactivation or subclinical infection) and it seems that its course depends on the HPV
serotype and other associated factors such as immune status, smoking, alcohol, environmental
factors, poor oral hygiene and eating habits [23].
Only two out of four HPV-DNA positive cases, which were positive for HPV16 and
HPV18, showed a diffuse p16INK4a pattern, representing a 2.4% of the total sample. Prelimi-
nary results from the Canadian study showed a HPV-DNA positivity of 6.2% of the dysplasias,
whereas 5.5% of all analysable cases demonstrated a p16INK4a diffuse pattern [20]. The study
also found that patients with oral dysplasia and focal p16INK4a expression had a significantly
lower risk of lesion progression, whereas a diffuse p16INK4a expression did not represent a spe-
cific biomarker of HPV-related precancerous lesions in the oral cavity [39]. Results from previ-
ous studies are summarized in S1 Table.
Our study has several strengths comprising the combined use of well-validated protocols
with highly sensitive assays for HPV-DNA detection and a marker of HPV related
Table 2. (Continued)
Characteristics OPLa samples (n = 83) No. (%)
Dysplasia moderate grade 12 (14.5)





Dysplasia severe grade 13 (15.7)







aOPL: Oral pre-malignant lesions.
bSD: Standard deviation.
https://doi.org/10.1371/journal.pone.0210070.t002
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transforming process such as p16INK4a expression at positive cases, as it is known that the mere
detection of HPV-DNA is not sufficient to establish causality in premalignant oral lesions and
HNSCCs [31]. Additionally, we evaluated the quality of our specimens by means of cellular
tubulin detection, which was positive in all cases. However, the study also has several limita-
tions. The HPV-positive cases were not tested for HPV E6/E7 mRNA expression, which is con-
sidered the gold-standard for classification of an HPV-caused cancer. Moreover, the
significance of p16-positivity in the oral cavity is debated [40,41]. However, our previous
results from the ICO study [27], where the cut-off for p16 positivity in HNSCCs was a staining
Fig 2. Pictures of HE and p16INK4a IHC of 3 out 4 HPV-DNA positive cases. Patient 1. (10X) Severe dysplasia at HE stain, HPV16 positivity and 26–50% staining for
p16. Patient 2. (10X) Oral lichen planus at HE stain, HPV 16 positivity and negative staining for p16. Patient 3. (10X) Moderate dysplasia at HE stain, HPV18 positivity
and 26–50% staining for p16. HE: hematoxilyn and eosin stain.
https://doi.org/10.1371/journal.pone.0210070.g002
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greater than 25%, showed that using p16INK4a and/or HPV-mRNA in addition to HPV-DNA
yielded the most accurate approximation to judge HPV carcinogenicity also in non-oropha-
ryngeal sites. We tested a small number of samples and we obtained low rates of HPV positiv-
ity. However, our population represents a specific geographic region, and our results are
consistent with other studies performed in the same area. The low rate of HPV-positivity also
deterred us to evaluate HPV infection as prognostic marker. The study was not population
based, and thus, it is not possible to exclude some degree of referral or selection bias. For this
reason, we tried to minimize this limitation selecting all cases consecutively. We neither have
information about the size of the oral lesions in most of the cases nor specific protocol about
the treatment of premalignant oral lesions.
After studying a cohort of patients with premalignant oral lesions using a highly sensitive
PCR technique for paraffin-embedded tissues, we found a low HPV-DNA attributable fraction
in premalignant lesions of the oral cavity, suggesting that HPV is unlikely to play a significant
role in oral carcinogenesis in our setting.
Supporting information
S1 Fig. Pathological form.
(DOCX)
S1 Table. Results from previous studies.
(DOCX)
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